Balyasny Asset Management
JANX icon

Balyasny Asset Management’s Janux Therapeutics JANX Stock Holding History

Balyasny Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.2M Buy
1,090,147
+204,596
+23% +$2.81M 0.02% 811
2025
Q4 		$12.2M Buy
+885,551
New +$20.8M 0.02% 934
2025
Q3 		– Sell
-10,054
Closed -$232K – 3183
2025
Q2 		$232K Buy
+10,054
New +$265K ﹤0.01% 2558
2024
Q4 		– Sell
-63,215
Closed -$2.87M – 2999
2024
Q3 		$2.87M Buy
+63,215
New +$2.75M ﹤0.01% 1518
2022
Q4 		– Sell
-12,182
Closed -$165K – 2998
2022
Q3 		$165K Buy
+12,182
New +$163K ﹤0.01% 2341

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Balyasny Asset Management's JANX Position: Q1 2026 in Review

Balyasny Asset Management increased its Janux Therapeutics (JANX) stake by 23% in Q1 2026, buying an estimated $2.81M and bringing the position to 1,090,147 shares worth $15.2M. The position accounts for 0.02% of the portfolio, ranked #811.

Balyasny Asset Management first reported a position in JANX in Q3 2022 and has held it in 5 quarters since. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Balyasny Asset Management held 1,090,147 shares of Janux Therapeutics worth $15.2M as of Q1 2026.
  • Balyasny Asset Management bought 204,596 Janux Therapeutics shares in Q1 2026, an estimated $2.81M.
  • Janux Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #811 holding.
  • Balyasny Asset Management first reported a position in Janux Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.